Date post: | 23-Dec-2015 |
Category: |
Documents |
Upload: | timothy-lawson |
View: | 221 times |
Download: | 2 times |
WHO Workshop on Assessment of Bioequivalence Data
Addis Ababa, 31. August – 3. September 2010
BCS-based Biowaivers
Dr. Henrike Potthast ([email protected])
WHO Workshop on Assessment Bioequivalence Data, Addis Ababa, 31. August-3.September, 2010
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
2 |
Basis for BCS-based Biowaiver Applications/Decisions
Basis for BCS-based Biowaiver Applications/Decisions
WHO – Technical Report Series No. 937, May 2006
Annex 7: Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability
Annex 8: Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate release, solid oral dosage forms
FDA - Guidance for Industry: “Waiver of in vivo bio-equivalence studies for immediate release solid oral dosage forms containing certain active moieties/active ingredients based on a Biopharmaceutics Classification System” (2000)
EU-guidance:“Note for Guidance on the Investigation of Bioavailability andBioequivalence” CPMP/EWP/QWP/1401/98 Rev1, Appendix 3
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
3 |
Definitions Definitions
Bioavailability – rate and extent at which a drug substance... becomes available in the general system (product characteristic!)
Bioequivalence – equivalent bioavailability within pre-set acceptance ranges
Pharmaceutical equivalence Bioequivalence
Bioequivalence Therapeutic equivalence
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
4 |
Definitions Definitions
Bioequivalence study
– in vivo comparison using humans as dissolution models
– ‚biological quality control‘– comparative evaluation of the formulation effect
Bioequivalence therapeutic equivalence
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
5 |
Definitions Definitions
BCS-based ‘Biowaiver’.....
.....is defined as
in vitro instead of in vivo ‘bioequivalence’ testing
comparison of test and reference
....is not defined as no equivalence test
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
6 |
Definitions Definitions
acc. to the FDA guidance:
”BCS-based biowaivers are intended only for
bioequivalence studies. They do not apply to
food effect bioavailability studies or other
pharmacokinetic studies.”
(e.g., rel. bioavailability)
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
7 |
BCS-based biowaiver
In vivo bioequivalence testing is generally required
but
” Such studies may be exempted if the absence of differences in the in vivo performance can be justified by satisfactory in vitro data.”
for oral immediate release dosage forms with systemic action!
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
8 |
BCS-based biowaiverBCS-based biowaiver
Evaluation of drug substance and
drug product
Drug substance
therapeutic aspects
physicochemical aspects
Drug product
in vitro dissolution
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
9 |
BCS-based biowaiverBCS-based biowaiver
Biowaiver justification
based on
”………criteria derived from the concepts underlying
the Biopharmaceutics Classification System ......”
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
10 |
BCS-based biowaiverBCS-based biowaiver
Biopharmaceutics Classification System (BCS)
dissolution
drug product drug substance in solution
membrane transport
drug substance in the system
simplified mechanistic view of bioavailability
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
11 |
Fig.1: Physicochemical properties that affect absorption (after oral administration) [H. van de Waterbeemd/ Eur J Pharm Sci 7 (1998), 1-3]
Melting point
Charge
Ionisa-tion
H-bonding
Lipophilicity
Size Shape
ChargeDistribution
Amphiphilicity
Solubility
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
12 |
BCS-based biowaiverBCS-based biowaiver
Solubility Permeability Dissolution Absorption
Pillars of the BCS
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
13 |
BCS-based biowaiverBCS-based biowaiver
High solubility
the highest single dose is completely soluble in 250 ml or less of aqueous solution at pH 1 - 6.8 (37 °C)
generate a pH-solubility profile
cave: possible stability problems have to be considered
Discussion on ‘intermediate solubility’, i.e., pH-dependent (high) solubility
Definition of low solubility?
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
14 |
BCS-based biowaiverBCS-based biowaiver
High solubility acc. to WHO
♦ highest dose recommended by WHO (as recommended in the WHO Model List of Essential Medicines)
or
♦ highest dose strength (if not listed s.o.)
please note the differences between guidelines!
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
15 |
BCS-based biowaiverBCS-based biowaiver
High permeability
♦ Revised EMA guidance: extent of absorption ≥ 85 % (absolute BA or mass balance data) or ‘known absorption’
♦ FDA guidance: absolute BA >90 %
♦ WHO guidance: extent of absorption at least 85 % in humans
Human data are preferred;
in-vitro data may be submitted if sufficiently justified and valid
Definition of low permeability?
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
16 |
BCS-based biowaiverBCS-based biowaiver
Methods to investigate permeability
♦ PK-studies (e.g. absolute BA or mass-balance studies)
♦ Human intestinal perfusion studies
♦ Animal models
♦ Caco 2 cell lines or other suitable, validated cell lines
(in-situ or in-vitro models for passively transported APIs only)
to be noted:
the stated methods assess the fraction dose absorbed ≠ BA, which can be reduced substantially by first-pass metabolism (see e.g. Propranolol)
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
17 |
BCS-based biowaiverBCS-based biowaiver
Supportive data to investigate permeability:
♦ In vivo or in situ perfusion using animal models and
♦ In vitro permeation across a monolayer of cultured epithelial cells like e.g. Caco 2 or other suitable, validated cell lines
are not acceptable on a stand-alone basis
(in-situ or in-vitro models for passively transported APIs only;
negative as well as positive controls needed)
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
18 |
BCS-based biowaiver
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
19 |
BCS-based biowaiverBCS-based biowaiver
Provided that ......
drug solubility is high,
permeability is limited,
excipients do not affect kinetics,
excipients do not interact ,.....
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
20 |
BCS-based biowaiverBCS-based biowaiver
....then very rapid dissolution (at least >85% in 15 min) of test
and reference may ensure similar product characteristics
because...
....absorption process is probably independent from
dissolution and not product related…
limited absorption kinetics due to poor drug permeability and/or gastric emptying
Biowaiver for BCS class III drugs (see WHO and revised EMA guidance)
BCS-class III?!
Fig. 1. Mean in vitro dissolution profiles of metformin for 500mg immediate-release tablet of
Glucophage® or Glucofit® in 0.1N HCI (○,●) pH 4.6 (□,■) and pH 6.8 (∆,▲) buffer solution.
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
22 |
BCS-class III?!BCS-class III?!
Fig. 2. Mean in vivo plasma conentration-time profiles of metformin in 12 healthy Chinese subjects after oral
administration of a 500mg immediate-release tablet of Glucophage (○) or Glucofit (●).Fig. 2
Fig.
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
23 |
BCS-class III?!BCS-class III?!
Fig. 1. Comparison of mean cimetidine released-time profiles obtained from dissolution testing of cimetidine
tablets containing methacrylate copolymer and Tagamet® tablets in different media. Each value is the mean of
six observations. Data for the Tagamet® tablet were obtained from dissolution testing in 0.01N hydrovhloric acid
(HCI) and simulated intestinal fluid without pancreatin (SIFsp): (a) 0.01N HCI, pH 2; (b) phosphate buffer, pH
4.5; (c) SIFsp, pH 6.8; and (d) fasted-state simulated intestinal fluid, pH 6.5 pancreatin. Clin Pharmacokinet. Jantratid et al 2006
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
24 |
BCS-class III?!BCS-class III?!
Fig. 2. Comparison of mean plasma cimetidine concentration-time profiles obtained after
administration of a singel oral dose of cimetidine tablets containing methacrylyte copolymer or
Tagamet® tablets. Each point represents the mean plasma cimetidine concentration (standarderror) from 12 subjects.
Clin Pharmacokinet. Jantratid et al 2006
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
25 |
BCS-based biowaiverBCS-based biowaiver
For drugs showing ....
‘very’ high permeability
pH-dependent solubility within the physiologically relevant pH range
.....an ‘intermediate solubility’ class is suggested
[Polli et al. J Pharm Sci 93 (2004) 1375; see WHO guidance]
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
26 |
BCS-based biowaiverBCS-based biowaiver
“pH-dependent soluble, highly permeable, weak
acidic, ionizable drug compounds may be handled
like BCS class I drugs” (e.g. chpt 8 in: Drug Bioavailability, van de Waterbeemd,
Lennernäs, Artursson (edts) 2003 Wiley-VCH)
in vitro dissolution requirements acc. to WHO guidance at least 85% within 30 min at pH 6.8 and
f2 testing for pH 1.2 and 4.5 profiles
but no biowaiver for weak basic drugs
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
27 |
BCS-based biowaiverBCS-based biowaiver
According to the WHO guideline drug substances
that belong to
BCS-class 1 and 3
and some of BCS class 2 (weak acids with high permeability)
..... are in principle eligible for the BCS-based biowaiver approach
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
28 |
BCS-based biowaiverBCS-based biowaiver
BCS-based biowaiver approach applicable…..
pro-drugs?
effective metabolites?
instability?
polymorphic forms?
stereochemistry (enantiomer/racemate)?
wide therapeutic dose range? ..........
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
29 |
BCS-based biowaiverBCS-based biowaiver
RISK assessment
(see e.g. WHO guidance; sect. 9.2 and 5.1.(a))
♦ “critical use medicines”
♦ “narrow therapeutic index drugs”
♦ “documented evidence for BA or BE problems
♦ “scientific evidence that API polymorphs, excipients or the manufacturing process affects BE”
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
30 |
BCS-based biowaiverBCS-based biowaiver
♦ „….if the fraction of the dose absorbed is the same, the human body should always do the same with the absorbed compound …Even in a disease state, this argument is still a valid statement.“
[Faassen et al. Clin Pharmacokinet 43 (2004)1117]
what does the product do to the drug substance?
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
31 |
BCS-based biowaiverBCS-based biowaiver
When are in vitro results sufficient for bioequivalence evaluation?
When is in vitro instead of in vivo bioequivalence testing scientifically justified (or even more restrictive)?
Minimizing risk by means of ‘worst case’ investigation?
Which in vitro investigations may be sufficient to detect
possible formulation related differences?
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
32 |
BCS-based biowaiverBCS-based biowaiver
in vitro dissolution objectives
quality control
justification of minor variations
iviv-correlation (e.g. major variations; bridging)
additional to BE studies
proportionality based biowaiver
BCS based biowaiver
….
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
33 |
BCS-based biowaiverBCS-based biowaiver
‘usual’ in vitro dissolution prerequisites
reasonable, stability-indicating, validated methods
discriminative methods
reproducible methods
biorelevant methods (?)
……one fits all?!
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
34 |
BCS-based biowaiverBCS-based biowaiver
in vitro dissolution and BCS concept
use of representative batches
meet prerequisites
ensure risk minimization
justify absence of difference
biorelevant?! 0
2
4
6
8
10
12
14
16
18
20
0 5 10 15 20
time%
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
35 |
BCS-based biowaiverBCS-based biowaiver
In vitro comparison of immediate release oral
drug products (T and R)
first option: very rapidly dissolving products
not less than 85 % of labeled amount are dissolved within 15 min in each of three buffers (pH 1.2, pH 4.5 acetate buffer, pH 6.8 phosphate buffer) – no further profile comparison of T and R is required
reasonable, validated experimental conditions/methods are strongly recommended!
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
36 |
BCS-based biowaiverBCS-based biowaiver
In vitro comparison of immediate release oral
drug products (T and R)
second option: rapidly dissolving products
not less than 85 % of labeled amount are dissolved within 30 min in each of three buffers (pH 1.2, pH 4.5 acetate buffer, pH 6.8 phosphate buffer)
reasonable, validated experimental conditions/methods are strongly recommended!
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
37 |
BCS-based biowaiverBCS-based biowaiver
Experimental conditions:
EU guidance – usually 50 rpm (paddle) or 100 rpm (basket); 900 ml; PhEur buffer; 37 °C;
sampling schedule
US-FDA guidance – ‚USP‘-conditions 50 rpm (paddle) or 100 rpm (basket); 900 ml; USP buffer; 37 °C
WHO – 75 rpm (paddle) or 100 rpm (basket); 900 ml or less; USP buffer; 37 °C
all: no surfactants!
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
38 |
BCS-based biowaiverBCS-based biowaiver
In vitro comparison of immediate release oral
drug products (T and R)
Proving similarity of dissolution profiles of T and R
e.g., using f2-test, unless similarity is obvious
(see e.g. WHO guidance sect. 9.2 or app. 1 of the revised EU guidance; note prerequisites)
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
39 |
BCS-based biowaiverBCS-based biowaiver
f2-test
acceptance value based on 10 % difference between profiles
„identical“ profiles: f2 =100
„similar“ profiles: f2 between 50 and 100
any other reasonable/justified test possible!
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
40 |
BCS-based biowaiverBCS-based biowaiver
requirement: either “very rapid” or “similar” in vitro dissolution
how similar is ‘similar’?
discussion of differences usually not appropriate
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
41 |
BCS-based biowaiverBCS-based biowaiver
BCS-based biowaiver in-vitro dissolution
no iviv correlation
no biorelevant conditions (except pH)
concept to justify absence of difference!
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
42 |
BCS-based biowaiverBCS-based biowaiver
finally EXCIPIENTS Evaluation of excipients (e.g., large amounts,
possible interactions....; e.g. Isoniazid J Pharm Sci 96 March 2007: “…permeability changes due to excipient interaction cannot be detected in vitro…”)
Evaluation of manufacturing processes in relation with critical physicochemical properties
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
43 |
BCS-based biowaiverBCS-based biowaiver
Risk assessment on EXCIPIENTS acc. to WHO
i) the excipient is present in the comparator product, or the excipient is present in a number of other products which contain the same API as the multisource drug product and which have marketing authorizations in countries participating in the International Committee on Harmonisation (ICH) or associated countries;
and
ii) the excipient is present in the multisource product in an amount similar to that in the comparator, or the excipient is present in the multisource drug product in an amount typically used for that type of dosage form.
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
44 |
BCS-based biowaiverBCS-based biowaiver
Excipients – generally
- Should be ‘well-known’
- Used in ‘usual amounts’
- Without relevant impact on the absorption process
Preferred for class I drugs and requested for class III: same excipients in
similar amounts as the reference
‘Critical’ excipients (e.g. surfactants, mannitol, sorbitol…)
should be qualitatively and quantitatively the same
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
45 |
BCS-based biowaiverBCS-based biowaiver
Summary Requirements - BCS class 1
„Dosage forms of APIs which are highly soluble, highly permeable (BCS Class 1), and are rapidly dissolving are eligible for a biowaiver based on the BCS provided:
(i) the dosage form is rapidly dissolving (as defined in section 9.1.2.2) and the dissolution profile of the multisource product is similar to that of the comparator product at pH 1.2, pH 4.5 and pH 6.8 buffer using the paddle method at 75 rpm or the basket method at 100 rpm (as described in section 9.2) and meets the criteria of dissolution profile similarity, f2 > 50 (or equivalent statistical criterion);
(ii) if both the comparator and the multisource dosage forms are very rapidly dissolving (as defined in section 9.1.2.1) the two products are deemed equivalent and a profile comparison is not necessary.“
(see WHO technical Report Series, No. 937, 2006 Annex 7 and 8)
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
46 |
BCS-based biowaiverBCS-based biowaiver
Summary Requirements - BCS class 3
„Dosage forms of APIs which are highly soluble and have low permeability (BCS Class 3) are eligible for biowaivers provided all the criteria (a–d) listed in section 9.2 are met and the risk–benefit is additionally addressed in terms of extent, site and mechanism of absorption.“
Very rapidly dissolving (release of >85 % within 15 min) in standard media pH 1.2, 4.5, and 6.8; 75 rpm (paddle) or 100 rpm (basket) applies to IR products containing class III APIs.
(see WHO technical Report Series, No. 937, 2006 Annex 7 and 8)
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
47 |
BCS-based biowaiverBCS-based biowaiver
Summary Requirements - BCS class 3 ctd.
- criteria (a–d) listed in section 9.2:
A biowaiver based on the BCS considers:
(a) the solubility and permeability of the API (see section 9.1);
(b) the similarity of the dissolution profiles of the multisource and comparator products in pH 1.2, 4.5 and 6.8 media (see below);
(c) the excipients used in the formulation (see below); and
(d) the risks of an incorrect biowaiver decision in terms of the therapeutic index of, and clinical indications for, the API (see section 5.1 for cases where an in vivo study would be required to demonstrate bioequivalence).
(see WHO technical Report Series, No. 937, 2006 Annex 7)
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
48 |
BCS-based biowaiverBCS-based biowaiver
Summary Requirements - BCS class 2
„Dosage forms of APIs with high solubility at pH 6.8 but not at pH 1.2 or 4.5 and with high permeability (by definition, some but not all BCS Class 2 compounds with weak acidic properties) are eligible for a biowaiver based on BCS provided that criteria (b), (c) and (d) described in section 9.2. are met, that the API has high permeability (i.e. the fraction absorbed is 85% or greater) and a dose:solubility ratio of 250 ml or less at pH 6.8, and that the multisource product:….
(see WHO technical Report Series, No. 937, 2006 Annex 7)
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
49 |
BCS-based biowaiverBCS-based biowaiver
Summary Requirements - BCS class 2 ctd…..
„is rapidly dissolving (85% in 30 minutes or less) in pH 6.8 buffer using the test procedure conforming to section 9.2;
and
(ii) the multisource product exhibits similar dissolution profiles, as determined with the f2 value or equivalent statistical evaluation, to those of the comparator product at the three pH values (pH 1.2, 4.5 and 6.8).“
(see WHO technical Report Series, No. 937, 2006 Annex 7)
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
50 |
BCS-based biowaiverBCS-based biowaiver
Summary Requirements - BCS class 2 ctd….
„For multisource products containing Class 2 APIs with dose:solubility ratios of 250 ml or less at pH 6.8, the excipients should additionally be critically evaluated in terms of type and amounts, e.g. of surfactants, in the formulation. Further, if the Cmax is critical to the therapeutic efficacy of the API, the risk of reaching an inappropriate biowaiver decision and its associated risks to public health and for individual patients may be deemed unacceptable.“
(see WHO technical Report Series, No. 937, 2006 Annex 7)
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
51 |
BCS-based biowaiverBCS-based biowaiver
meaningful literature data may be used for drug substance characteristics (and excipients)
product related data must always be actually generated for the particular product
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
52 |
BCS-based biowaiverBCS-based biowaiver
Current recommendation for TB drugs
no BCS-based biowaiver for RMP
‘regular’ BCS-based biowaiver possible for levofloxacin and ofloxacin (“rapid dissolution”)
currently a BCS-based biowaiver is possible for isoniazid (cave: excipients!), ethambutol and pyrazinamide if the same “very rapid” dissolution (T and R) is demonstrated
see specific, currently published WHO guidance documents at: http://healthtech.who.int/pq/info_applicants/info_for_applicants_BE_studies.htm
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
53 |
BCS-based biowaiverBCS-based biowaiver
Current recommendation for TB drugs
however – a BCS-based biowaiver is not possible due to the comparator(!) in the case of…
Ofloxacine (since rapid dissolution is not achieved)
Ethambutol (since very rapid dissolution is not achieved)
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
54 |
BCS-based biowaiverBCS-based biowaiver
Current recommendation for antiretroviral drugs
a BCS-based biowaiver is possible for
♦ lamivudine♦ stavudine♦ zidovudine
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
55 |
BCS-based biowaiverBCS-based biowaiver
♦ „….Risk assessment: only if the risk of an incorrect biowaiver decision and an evaluation of the consequences (of an incorrect, biowaiver-based equivalence decision) in terms of public health and risks to individual patients is outweighed by the potential benefits acrued from the biowaiver approach may the biowaiver procedure be applied…“
[WHO Technical Report Series, No. 937, 2006; Annex 8]
is the concept scientifically sound?
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
56 |
BCS-based biowaiverBCS-based biowaiver
BCS-based biowaiver are not just in-vitro dissolution, but in-vitro dissolution is meant to be an important part of BCS-based biowaiver applications
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
57 |
BCS-based biowaiverBCS-based biowaiver
Minimize the risk by thorough and correct …
drug substance classification
In-vitro dissolution (incl. profile comparison)
demonstration that excipients are well-established (?!?) will not differ in terms of their effect on absorption will not lead to interactions that alter pharmacokinetics
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
58 |
BCS-based biowaiverBCS-based biowaiver
Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM: Biowaiver monographs for immediate release solid oral dosage forms: Pyrazinamide; J Pharm Sci. 2008 Feb 12; [Epub ahead of print]
Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM: Biowaiver monographs for immediate release solid oral dosage forms: ethambutol dihydrochloride; J Pharm Sci. 2008 Apr;97(4):1350-60.
Vogt M, Derendorf H, Krämer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM: Biowaiver monographs for immediate release solid oral dosage forms: prednisone; J Pharm Sci. 2007 Jun;96(6):1480-9.
Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM; International Pharmaceutical Federation, Groupe BCS: Biowaiver monographs for immediate release solid oral dosage forms: isoniazid; J Pharm Sci. 2007 Mar;96(3):522-31.
Kalantzi L, Reppas C, Dressman JB, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky SA, Barends DM: Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol); J Pharm Sci. 2006 Jan;95(1):4-14.
Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, Vogelpoel H, Barends DM: Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen; J Pharm Sci. 2005 Oct;94(10):2121-31.
Kortejärvi H, Yliperttula M, Dressman JB, Junginger HE, Midha KK, Shah VP, Barends DM: Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride; J Pharm Sci. 2005 Aug;94(8):1617-25.
Verbeeck RK, Junginger HE, Midha KK, Shah VP, Barends DM: Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride; J Pharm Sci. 2005 Jul;94(7):1389-95.
……….
WHO Workshop on Assessment of Bioequivalence Data31. August – 3. September 2010, Addis Ababa
59 |
BCS-based biowaiverBCS-based biowaiver
THANK YOU FOR YOUR ATTENTION!